𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy

✍ Scribed by Lucie Benesova; Milos Pesek; Barbora Belsanova; Patrik Sekerka; Marek Minarik


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
249 KB
Volume
33
Category
Article
ISSN
1615-9306

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The presence of activating mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene has been attributed to a positive response to biological therapy of lung cancer by small‐molecular tyrosine kinase inhibitors, gefitinib and erlotinib. Among the two most significant mutation types are deletions in exon 19 and a single point substitution in exon 21 (termed L858R). The exon 19 deletions can readily be examined by fragment analysis, due to the characteristic length difference between the normal and mutated PCR product. Analysis of the L858R point mutation, however, presents a greater challenge. The current paper is aimed at developing a sensitive, yet simple, low‐cost mutation detection assay directed at the L858R mutation using a method based on CE of heteroduplexes under partial denaturing conditions. We perform optimization of separation conditions on different commercial instruments including ones equipped with 8, 16 and 96 capillaries. We present normalized migration reproducibility in the range from 1 (8 and 16) to 5% (96) RSD. A reliable distinction of the R836R silent polymorphism from a potential presence of the L858R mutation is also demonstrated. In its implementation, the presented assay is just another application running on a conventional CE platform without the need of dedicated instrumentation.


📜 SIMILAR VOLUMES


Detection of epidermal growth factor rec
✍ Chen He; Ming Liu; Chengzhi Zhou; Jiexia Zhang; Ming Ouyang; Nanshan Zhong; Jun 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 260 KB 👁 2 views

## Abstract The high frequency of epidermal growth factor receptor (__EGFR__) mutations in tyrosine kinase inhibitor‐responsive non‐small‐cell lung cancer (NSCLC) cases is now well established, highlighting the predictive value of activating __EGFR__ mutations in guiding the clinical use of __EGFR_